BeOne Medicines counsel exercises options, sells ADS
BeOne Medicines Ltd. SVP and general counsel Lee Chan Henry exercised options for 21,697 ordinary shares on July 22, 2026, at exercise prices of $14.96, $16.41 and $12.23 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BeOne Medicines Ltd. SVP and general counsel Lee Chan Henry exercised options for 21,697 ordinary shares on July 22, 2026, at exercise prices of $14.96, $16.41 and $12.23 per share. He acquired American Depositary Shares at prices of $194.47, $213.32 and $159.03 per ADS, and sold 1,669 ADS at $325 pursuant to a Rule 10b5-1 trading plan adopted on May 29, 2026. After these transactions he held 338,884 ordinary shares directly.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Share Option (Right to Buy) F3, F4 | 6,682 | $0.00 | $0.00 |
| Exercise | Share Option (Right to Buy) F3, F5 | 8,645 | $0.00 | $0.00 |
| Exercise | Share Option (Right to Buy) F3, F6 | 6,370 | $0.00 | $0.00 |
| Exercise | American Depositary Shares F1 | 514 | $194.47 | $100K |
| Exercise | American Depositary Shares F1 | 665 | $213.32 | $142K |
| Exercise | American Depositary Shares F1 | 490 | $159.03 | $78K |
| Sale | American Depositary Shares F1, F2 | 1,669 | $325.00 | $542K |
| Holding | Ordinary Shares | -- | -- | -- |
Footnotes (6)
- F1. Each American Depositary Share represents 13 Ordinary Shares.
- F2. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2026.
- F3. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.
- F4. These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
- F5. These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
- F6. These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
accelerated vesting financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did BeOne Medicines (ONC) report for Lee Chan Henry?
Were the BeOne Medicines (ONC) insider sales made under a Rule 10b5-1 plan?
What option exercises did the BeOne Medicines (ONC) executive complete?
AI-generated analysis. How Rhea-AI works. Not financial advice.